Related Experiment Video
Updated: Jul 6, 2026
A Tailored HPLC Purification Protocol That Yields High-purity Amyloid Beta 42 and Amyloid Beta 40 Peptides, Capable of Oligomer Formation
Published on: March 27, 2017
Evaluation of the Therapeutic Effects of Beta2-Microglobulin Adsorption on Dialysis-Related Amyloidosis Using a
Chikao Onogi1,2, Akihito Tanaka3, Kazuhiro Furuhashi4
1Department of Nephrology, Nagoya University, Graduate School of Medicine, Nagoya, Japan.
Introduction:
Dialysis-related amyloidosis (DRA) is a refractory complication of long-term dialysis caused by β2-microglobulin (β2MG) deposition. While β2MG adsorption columns remove β2MG, their impact on preventing re-surgery remains unclear.
Methods:
This a noninterventional, population-based cohort study used a large-scale medical claims database. This study included patients with chronic kidney disease undergoing maintenance hemodialysis (HD) and diagnosed with DRA. The exposure group received β2MG adsorption column therapy, while the control group was divided into online hemodiafiltration (OHDF) and HD subgroups. The primary endpoint was carpal tunnel or trigger finger release.
Results:
Among 3,946 eligible patients, 212 patients in the β2MG adsorption column group, 139 in the OHDF group, and 237 in the HD group were included; the primary endpoint occurred in 28 (13.2%), 21 (15.1%), and 37 (15.6%) patients, respectively. Although there was a trend toward a lower incidence in the β2MG adsorption column group, no significant difference was observed (p = 0.43). The adjusted hazard ratio for the β2MG adsorption column group (HD group as reference) tended to be low (0.68, 95% CI: 0.41-1.13), but this difference was not significant.
Conclusions:
Although there was no statistically significant difference, the findings suggest that the β2MG adsorption column may help slow DRA progression.
Insights
Beta2-microglobulin (β2MG) adsorption columns may help slow Dialysis-Related Amyloidosis (DRA) progression in hemodialysis patients. While not statistically significant, the therapy showed a trend towards reduced re-surgery rates for carpal tunnel or trigger finger release.
Area of Science:
- Nephrology
- Biomedical Engineering
Background:
- Dialysis-Related Amyloidosis (DRA) is a serious complication of long-term dialysis.
- It results from beta2-microglobulin (β2MG) deposition.
- The effectiveness of β2MG adsorption columns in preventing DRA-related surgeries is not well-established.
Purpose of the Study:
- To investigate the impact of β2MG adsorption column therapy on preventing re-surgeries in patients with DRA.
- To compare the incidence of carpal tunnel or trigger finger release in patients treated with β2MG adsorption columns versus other dialysis modalities.
Main Methods:
- A non-interventional, population-based cohort study using a large medical claims database.
- Inclusion of patients with Chronic Kidney Disease (CKD) undergoing maintenance hemodialysis (HD) and diagnosed with DRA.
- Comparison between a β2MG adsorption column group and control groups (on-line hemodiafiltration [OHDF] and HD).
Main Results:
- Among 3,946 eligible patients, 212 received β2MG adsorption columns, 139 received OHDF, and 237 received HD.
- The primary endpoint (carpal tunnel or trigger finger release) occurred in 13.2% (β2MG group), 15.1% (OHDF group), and 15.6% (HD group).
- No statistically significant difference in re-surgery rates was observed between groups (P=0.43).
Conclusions:
- While not statistically significant, β2MG adsorption column therapy showed a trend towards slowing DRA progression.
- The adjusted hazard ratio suggested a potential benefit, though not reaching statistical significance.
- Further research may be needed to confirm the clinical utility of β2MG adsorption columns in managing DRA.
